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OBJECTIVE: All chemotherapy regimens are associated with
some degree of adverse events. The more severe adverse events
require hospitalization and may be associated with high costs.
One adverse event that may be serious is infection and in par-
ticular infection because of neutropenia. The objective of this
study was to retrospectively assess the hospitalization costs of
infections and neutropenia in cancer patients. METHODS: Indi-
vidual patient data on costs, diagnoses, and length of stay were
collected from the largest cost per patient inpatient database in
Sweden. The time period was January 1999 to January 2000.
The hospitals included in the database all have a detailed
resource tracking and cost assignment system for determining the
individual cost per stay. All non-surgical patients who had the
combination of a cancer ICD-10 (C000 to C997) and an infec-
tion diagnosis recorded in the database were selected. Patients
who also had a neutropenia (D709) diagnosis recorded were
selected and studied as a subsample of the whole sample.
RESULTS: There were 2378 patients who had a cancer and an
infection diagnosis. Their mean cost was (SEK) 69,700 and the
mean length of stay was 12.3 days. The average age was 62 years
and there were 59% women. Patients with a principal cancer
diagnosis had greater costs than patients with a secondary cancer
diagnosis, 85,500 versus 50,600. Out of the 2378 patients there
were 52 who had both neutropenia and an infection. Their mean
age was 55 years. There were slightly more women than men,
54%. The mean cost was (SEK) 77,900 and the mean length of
stay was 12.9 days. CONCLUSIONS: The hospitalization costs
of infections and neutropenia in cancer patients are signiﬁcant.
When assessing the costs of chemotherapy treatments, not only
pharmaceutical costs, but also costs of adverse events should be
included.
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PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)
Haiderali A1, Chin W2
1AstraZeneca Canada Inc, Mississauga, Ontario, Canada; 2Axia
Research Inc, Salt Lake City, UT, USA
OBJECTIVES: The objective of this study was to determine the
lifetime cost of treating NSCLC patients with geﬁtinib. NSCLC
is a fatal malignancy that responds poorly to chemotherapy. Best
Supportive Care (BSC) is frequently offered when management
with anticancer treatments is not feasible. Geﬁtinib (“Iressa”) is
the ﬁrst epidermal growth factor receptor tyrosine kinase
inhibitor approved for the treatment of patients with locally
advanced or metastatic NSCLC. METHODS: Duration of geﬁ-
tinib treatment was estimated by the time to progression in
IDEAL 2, a phase II clinical trial involving patients with
advanced or metastatic NSCLC who had previously received
platinum-based chemotherapy. Post progression, patients were
assumed to receive BSC. Resource utilization was estimated from
the clinical trial. The cost of BSC following chemotherapy was
provided by CancerCare Manitoba. Costs were expressed in
Canadian dollars (2003). RESULTS: Patients (n = 102) received
geﬁtinib 250mg daily. Over 40% of patients achieved a complete
response, partial response or stable disease, and clinically signif-
icant improvement in disease-related symptoms occurred in most
of these patients. Median time to progression was 1.9 months.
The median survival time was 7 months. The tolerability proﬁle
of geﬁtinib was mild and there was a low incidence of grade 3/4
adverse reactions. The lifetime cost of treating a patient with geﬁ-
tinib plus BSC was estimated at $14,496. In sensitivity analyses,
that lifetime cost ranged from $13,822 up to $24,915. CONL-
CUSIONS: The lifetime cost to treat a patient with geﬁtinib plus
BSC was $14,496, which is comparable to costs for other
chemotherapies for NSCLC. For example, the lifetime cost of
second-line docetaxel was $17,739 (1999 dollars [$19,389 in
2003 dollars]) and for other chemotherapies, lifetime costs
ranged from $24,828 up to $41,178 (1995 dollars [$29,059 to
$48,196 in 2003 dollars]). “Iressa” is a trademark of the
AstraZeneca group of companies.
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VERSUS IV ZOLEDRONIC ACID OR IV GENERIC
PAMIDRONATE FOR BONE METASTASES FROM BREAST
CANCER IN PATIENTS RECEIVING ORAL HORMONAL
THERAPY IN THE UK
De Cock E1, Hutton J1, Barrett-Lee P2, Canney P3, Body JJ4,
Neary M5, Lewis GJ6
1MEDTAP International Inc, London, UK; 2Velindre Cancer Centre,
Cardiff, UK; 3Western Hospital, Glasgow, UK; 4Université Libre de
Bruxelles, Brussels, Belgium; 5Hoffmann-La Roche Inc, Nutley, NJ, USA;
6Roche Products Limited, Welwyn Garden City, Herts, UK
OBJECTIVES: Oral ibandronate (ibandronic acid) is a bisphos-
phonate approved in the UK for treatment of bone metastases
from breast cancer. Administration of oral ibandronate once-
daily can be easily combined with oral hormonal therapy, saving
costs of iv bisphosphonate administration and monitoring. We
used cost-effectiveness (C/E) modelling to compare oral iban-
dronate with iv zoledronic acid or iv generic pamidronate in this
setting. METHODS: The model assumed a UK NHS perspective
with a duration of 14.3 months (expected average survival).
Patients were assumed to receive oral hormonal therapy for 53%
of their survival. Primary outcomes were direct Health Care costs
and QALYs. Resource use data for iv bisphosphonates came
from a published micro-costing study (validated through review
by a UK clinician); costs were calculated using a unit cost data-
base. Monthly drug acquisition costs were £195 for oral iban-
dronate and iv zoledronic acid, and £165 for iv generic
pamidronate. The cost of managing skeletal-related events
(SREs) came from a published study. Renal adverse events with
monitoring and treatment costs were assumed for zoledonic acid.
Efﬁcacy was calculated as the relative risk reduction (RR) of
SREs; utility scores were applied to time with/without an SRE
(SRE duration assumed 1 month). RESULTS: The projected total
cost was £297 less/patient with oral ibandronate than with zole-
dronic acid, and £1087 less than with generic pamidronate. Oral
ibandronate led to a gain of 0.02 QALYs (due to SRE RR and
bone pain relief), making it the economically dominant treatment
option. For completeness, C/E results for iv ibandronate will also
be presented, demonstrating C/E. CONCLUSIONS: This study
demonstrated the use of C/E modelling to compare oral versus
iv bisphosphonates using published data validated by expert clin-
ician review. Oral ibandronate was found to be cost-effective for
the management of bone metastases from breast cancer in
patients receiving oral hormonal therapy.
PCN9
A TIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS
IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC
BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK
Wardley A1, Body JJ2, Neary M3, Lewis G4
1Christie Hospital, Manchester, UK; 2Université Libre de Bruxelles,
Brussels, Belgium; 3Hoffmann-La Roche Inc, Nutley, NJ, USA; 4Roche
Products Limited, Welwyn Garden City, Herts, UK
OBJECTIVES: Oral bisphosphonates should reduce medical
resource use versus iv infusions. A US study used time-in-motion
methods to assess resource use for iv zoledronic acid vs. iv
pamidronate (DesHarnais CL et al, Support Care Cancer 2001).
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We used time-in-motion methods in a pharmacoeconomic sub-
study to a clinical trial to estimate differences in resource use and
costs between oral ibandronate (ibandronic acid) and iv zole-
dronic acid. METHODS: At the Week 8 study visit, administra-
tion, monitoring and the treatment of drug-related adverse
events were recorded in patients receiving oral ibandronate 
50mg/day (n = 4) or iv zoledronic acid 4mg every 3–4 weeks (n
= 5) at 2 centres in the UK. No patients were receiving iv
chemotherapy. Data was collected using a detailed nurse work-
sheet (diary), designed and pilot-tested in one center. Total use
of infusion supplies, medications, laboratory tests, procedures,
staff time and total time in the clinic were also recorded.
RESULTS: Administration of iv zoledronic acid required >1.5
hours more clinic time per visit and approximately 1 hour more
clinician and nurse time than oral ibandronate, due to infusion
time and patient monitoring. Over a 12-month period, the addi-
tional clinician and nurse time required for iv zoledronic acid
administration would be about 16 hours more than with oral
ibandronate, and there would be about 36 additional clinic
hours, including 28 hours for iv preparation and infusion alone.
Details on medical resource use for infusion-related supplies,
medications, laboratory tests will be presented. CONCLU-
SIONS: Oral ibandronate reduced the burden on health care pro-
fessionals, giving staff more time to treat patients, increasing
productivity. The absence of iv administration also frees patient
beds and improves capacity within health care systems. The
potential beneﬁts will be greatest for patients receiving 
oral anticancer therapies, or those who have completed iv
chemotherapy.
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COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER
DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)
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OBJECTIVES: To analyse the cost-effectiveness of CAD in breast
cancer diagnostic in comparison to normal procedure from the
perspective of statutory health insurance (SHI). METHODS: To
compare the effectiveness with and without CAD, total costs of
diagnostic measures were calculated by a Markov-model. Model
structure, transition possibilities, procedures within therapies
and complications were ascertained by a Delphi-panel. Subse-
quently, costs of therapy per patient with and without CAD were
calculated. Fur-thermore, costs of successive therapy of unde-
tected cancer without CAD were consid-ered. Based on litera-
ture, an increase of 19.5% in detecting breast cancer with CAD
was determined. Moreover the assumption was made, that with
CAD 19.5% of cancers could be detected at an earlier stage.
RESULTS: Based on perspective of the SHI, diagnostic and
therapy of 10,000 mammography patients from the Markov-
cohort caused total costs in amount of 2,298,048€ without CAD
(229.80€ per patient) and 2,352,635€ with CAD (235.26€ per
patient). By consideration of the effectiveness parameter (number
of detected breast cancers per 10,000 patients, 0.01912 without
CAD, 0.02285 with CAD), the effectiveness-adjusted costs
amounted to: without CAD 12,019€, with CAD 10,296€. Thus,
the implementation of CAD proves to be more cost-effective due
to a higher sensitivity of the diagnostic procedure.Subsequently,
two sensitivity-analyses were conducted to test robustness of this
model for cost effectiveness and for costs per patient relative to
the price for CAD. CONCLUSIONS: Diagnosis costs per patient
are higher with CAD compared to normal procedure. However,
more breast cancers can be detected and treated at an earlier
stage. Therapeutic costs per patient are lower; therefore imple-
mentation of CAD is more cost-effective. As far as Germany is
concerned, 2.691 additional breast cancers can be detected every
year if CAD would be included in breast cancer diagnosis.
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OBJECTIVES: Cost-effectiveness (C/E) studies of oral vs iv reg-
imens are important, with the availability of oral regimens
having “iv efﬁcacy”, and some iv regimens being available as
generics. C/E of oral ibandronate (ibandronic acid) versus iv
zoledronic acid or iv generic pamidronate was assessed in breast
cancer patients with metastatic bone disease undergoing iv
chemotherapy. METHODS: The model assumed a UK NHS per-
spective, 14.3 months expected average survival, concurrent iv
chemotherapy lasting 4 months, and speciﬁed probabilities for
bisphosphonate discontinuation. Primary outcomes were direct
Health Care costs and QALYs. Resource use for iv bisphospho-
nates was obtained from a published micro-costing study (vali-
dated by UK clinician); the cost of managing skeletal-related
events (SREs) came from published literature. Other costs were
calculated using a unit cost database. Monthly drug costs were
£195 for oral ibandronate and iv zoledronic acid, and £165 for
iv generic pamidronate. Renal AEs with monitoring and treat-
ment costs were assumed for zoledonic acid. Efﬁcacy was
assessed as the relative risk reduction (RR) of SREs (assuming
SRE duration of 1 month). Utilities were applied to time
with/without SRE, to adjust survival for patient QOL.
RESULTS: Projected total cost (including drug) was £386
less/patient for oral ibandronate than for zoledronic acid, and
£1171 less/patient than for generic pamidronate. Due to SRE RR
and pain relief, oral ibandronate gained 0.02 QALYs, making it
the economically dominant option versus zoledronic acid or
generic pamidronate. For completeness, C/E results for iv iban-
dronate will also be presented, demonstrating C/E. CONCLU-
SIONS: Oral ibandronate was highly cost-effective compared
with either iv zoledronic acid or generic pamidronate. The 
efﬁcacy of oral ibandronate in preventing SREs and sustaining
relief from metastatic bone pain is likely to lead to QALY gains,
with cost savings due to reduced Health Care staff time for
treatment of SREs, bisphosphonate administration, and patient
monitoring.
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AND/OR COLONOSCOPIC SURVEILLANCE IN THE
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OBJECTIVES: To compare the medical and economical impact
of four strategies in the prevention of colorectal cancer (CRC)
in France: 1) no treatment no surveillance; 2) chemoprevention
with 325mg daily aspirin; 3) colonoscopic surveillance with a 3,
5 or 10-year periodicity according to recent guidelines; and 4) a
combination of the two latter ones. METHODS: A Markov deci-
sion model was built, following a ﬁctive 50-year-old cohort
